Lynette Sholl
Overview
Explore the profile of Lynette Sholl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dacic S, Travis W, Redman M, Saqi A, Cooper W, Borczuk A, et al.
J Thorac Oncol
. 2023 Sep;
18(10):1290-1302.
PMID: 37702631
Introduction: Pathologic response has been proposed as an early clinical trial end point of survival after neoadjuvant treatment in clinical trials of NSCLC. The International Association for the Study of...
12.
Roberts T, Kehl K, Brooks G, Sholl L, Wright A, Landrum M, et al.
JAMA Netw Open
. 2023 Apr;
6(4):e2310809.
PMID: 37115543
Importance: All patients with newly diagnosed non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) should receive molecular testing to identify those who can benefit from targeted therapies. However, many...
13.
Wang S, Rong R, Yang D, Fujimoto J, Bishop J, Yan S, et al.
J Clin Invest
. 2023 Jan;
133(2).
PMID: 36647832
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effective for many patients with lung cancer with EGFR mutations. However, not all patients are responsive to EGFR TKIs,...
14.
Keller R, Mazor T, Sholl L, Aguirre A, Singh H, Sethi N, et al.
JCO Precis Oncol
. 2023 Jan;
7:e2200342.
PMID: 36634297
Purpose: With the growing number of available targeted therapeutics and molecular biomarkers, the optimal care of patients with cancer now depends on a comprehensive understanding of the rapidly evolving landscape...
15.
Vikas P, Messersmith H, Compton C, Sholl L, Broaddus R, Davis A, et al.
J Clin Oncol
. 2023 Jan;
41(10):1943-1948.
PMID: 36603179
Purpose: The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO...
16.
Thunnissen E, Beasley M, Borczuk A, Dacic S, Kerr K, Lissenberg-Witte B, et al.
J Thorac Oncol
. 2022 Dec;
18(4):447-462.
PMID: 36503176
Introduction: Since the eight edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM classification system, the primary tumor pT stage is determined on the...
17.
Klein H, Mazor T, Siegel E, Trukhanov P, Ovalle A, Del Vecchio Fitz C, et al.
NPJ Precis Oncol
. 2022 Oct;
6(1):69.
PMID: 36202909
Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs...
18.
Willard N, Sholl L, Aisner D
Clin Lab Med
. 2022 Sep;
42(3):309-323.
PMID: 36150814
The genetic testing of solid tumors has evolved rapidly. With an ever-increasing number of clinically significant and/or actionable gene alterations in addition to increasing biologic, gene, or mutation-specific therapies, single-target...
19.
Schaller T, Markl B, Claus R, Sholl L, Hornick J, Giannetti M, et al.
Allergy
. 2022 Mar;
77(7):2237-2239.
PMID: 35340030
No abstract available.
20.
Vokes N, Chambers E, Nguyen T, Coolidge A, Lydon C, Le X, et al.
J Thorac Oncol
. 2022 Mar;
17(6):779-792.
PMID: 35331964
Introduction: Patients with EGFR-mutant NSCLC experience variable duration of benefit on EGFR tyrosine kinase inhibitors. The effect of concurrent genomic alterations on outcome has been incompletely described. Methods: In this...